Pharmaceutical advertising and compliance

The EU regulates advertising of pharmaceutical products on a member state level. This requires expertise on a member state level.

DADA is an established service provider in the field of pharmaceutical advertising. Our dedicated and qualified team supports you in obtaining high quality and compliant pharmaceutical advertising.

DADA provides compliance review for the full spectrum of pharmaceutical advertising; written and oral promotion, patient support programmes and financial inducements. We serve innovator and generic companies, and their prescription-only and OTC pharmaceutical products.

The compliance review is conducted as per the applicable legislation and selfregulation, where necessary complemented by the EU Directive and EFPIA Code. Our consolidated network of partners allows us to coordinate projects at European level.

Quantitative Structure-Activity Relationship (QSAR) assessment according ICH-M7

DADA Consultancy carries out database and literature searches for carcinogenicity and bacterial mutagenicity data, computational toxicology assessment by two complimentary (Q)SAR prediction methodologies (one expert-rule and one statistical-based) for bacterial mutagenicity and expert analysis including read-across all according ICH-M7.

Phase 1 Environmental Risk Assessment (ERA)

DADA Consultancy carries out the Phase 1 ERA risk assessment and Phase 1 PBT (Persistent, Bioaccumulative and Toxic) risk assessment according current guidelines and helps you avoid costly Phase 2 ERA risk assessment.

Health based exposure limits (HBEL)

DADA Consultancy carries out the evaluation of all available pharmacological and toxicological data, and in concordance with ICH guidelines, constitutes a permitted daily exposure (PDE) report including a clear scientific rationale.

Derived threshold values can be used as a risk identification tool and can also be used to justify carry over limits used in cleaning validation.

Early Access programs

DADA has experience in planning and applying for Early Access Program authorisations in the BeNeLux. These programs ensure access of clinical trial participants to their successful treatment after finalisation of the clinical trial until marketing of the drug, the compassionate availability of the medicine after MA application but before commercialisation and supply on a per-named-patient basis of medicines without an MA in the concerned countries.

 

 

network test

Dutch-Belgian Group

PIL user testing